Dr. Boxer received his MD and PhD degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center and a residency in Neurology at Stanford University Medical Center. He completed a fellowship in behavioral neurology at UCSF.

Dr. Boxer is an Associate Professor of Neurology and the Vera and John Graziadio Scholar in Alzheimer’s Disease Research. He directs the Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Center. He participates in the evaluation and management of patients in the Memory and Aging Clinic and attends on the Moffitt Inpatient Neurology Service.

Dr. Boxer’s research uses quantitative eye movement (watch a video on this study) and neuroimaging (MRI and PET) measurements to study the pathophysiology of cognitive and motor impairments in normal aging, mild cognitive impairment, Alzheimer’s disease, frontotemporal lobar degeneration, progressive supranuclear palsy (PSP) and corticobasal degeneration. He is the lead principal investigator of the first US multicenter, randomized, placebo-controlled, clinical trial of a therapeutic agent for frontotemporal dementia (memantine/Namenda®) and an international, phase 2/3, randomized, placebo-controlled trial of the microtubule stabilizing agent, davunetide (NAP, Al-108), for PSP. Dr. Boxer is the recipient of the 2002 Edwin Boldrey Award from the San Francisco Neurological Society, the 2005 John Douglas French Foundation Alzheimer’s Award and a 2009 Hellman Foundation Scientist Award. He also leads the FTD Treatment Study Group (FTSG), a group looking to speed the development of new therapies for FTD.

Dr. Geschwind received his MD and PhD (neuroscience) degrees through the National Institutes of Health-sponsored Medical Scientist Training Program at the Albert Einstein College of Medicine in New York. He completed his internship in internal medicine at the University of California, Los Angeles Medical Center, his neurology residency at the Johns Hopkins University School of Medicine in Baltimore and his fellowship in behavioral neurology at the UCSF Memory and Aging Center (MAC). He has been at the Memory and Aging Center since 2003.

Dr. Geschwind evaluates patients in the MAC new patient clinic and participates in the management and care for these patients in the MAC continuity clinic. He is active in the training of medical students and residents at UCSF. Dr. Geschwind teaches a national course and lectures, both nationally and internationally, on the assessment of rapidly progressive dementias, including human prion diseases.

Dr. Geschwind's primary research interest is the assessment and treatment of rapidly progressive dementias, including prion diseases such as Creutzfeldt-Jakob disease (CJD). Dr. Geschwind helped establish an inpatient hospital program for the assessment of rapidly progressive dementias at UCSF, one of the first of its kind in the country. He ran the first ever US treatment study for CJD. He also has an active research interest in cognitive dysfunction in movement disorders, such as Huntington's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and other Parkinsonian dementias.

Dr. Miller holds the A.W. and Mary Margaret Clausen Distinguished Professorship in Neurology at the University of California, San Francisco (UCSF). He directs the busy UCSF dementia center where patients in the San Francisco Bay Area receive comprehensive clinical evaluations. His goal is the delivery of model care to all of the patients who enter the clinical and research programs at the UCSF Memory and Aging Center.

Dr. Miller is a behavioral neurologist focused in dementia with special interests in brain and behavior relationships as well as the genetic and molecular underpinnings of disease. His work in frontotemporal dementia (FTD) emphasizes both the behavioral and emotional deficits that characterize these patients, while simultaneously noting the visual creativity that can emerge in the setting of FTD. He is the principal investigator of the NIH-sponsored Alzheimer’s Disease Research Center (ADRC) and an NIH-funded program project on FTD called Frontotemporal Dementia: Genes, Imaging and Emotions. He oversees a healthy aging program supported through the Hellman Center, which includes an artist in residence program. In addition, he helps lead two philanthropy-funded research consortia, the Tau Consortium and Consortium for Frontotemporal Research, focused around developing treatments for tau and progranulin disorders respectively. Also, he has worked with the National Football League to help with the education and assessment of players related to brain health. Dr. Miller teaches extensively and runs the Behavioral Neurology Fellowship at UCSF.

Dr. Miller has received many awards including the Potamkin Award from the American Academy of Neurology, the Raymond Adams Lecture at the American Neurological Association, the Elliot Royer Award from the San Francisco Neurological community, the UCSF Annual Faculty Research Lectureship in Clinical Science, the UCSF Academic Senate Distinction in Mentoring Award, and the Gene D. Cohen Research Award in Creativity and Aging from the National Center for Creative Aging. He has authored The Human Frontal Lobes, The Behavioral Neurology of Dementia and extensive publications regarding dementia. He has been featured in Fortune magazine and the New York Times, as well as on "Charlie Rose," "PBS NewsHour" and other media. For nearly three decades, Dr. Miller has been the scientific director for the philanthropic organization The John Douglas French Alzheimer’s Foundation, a private philanthropic organization that funds basic science research in Alzheimer’s disease.